The Global APAC In situ Hybridization Market is projected to reach USD 744 million by 2027 from USD 363 million in 2022, at a CAGR of 15.4% during the forecast period. The growth is largely driven by increasing government and private funding in life sciences and cancer research, the increasing number of reagent rental agreements, and the application of innovative technologies and methodologies in the fields of tissue and in vitro diagnostics.

Key drivers of the in situ hybridization market include rising incidence of genetic disorders and cancer, and growing awareness of companion diagnostics. However, a shortage of skilled professionals poses a significant challenge to the growth of this market.

Download Report Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=212028829

The FISH segment dominates the in situ hybridization (ISH) market through 2020-2027.

The global in situ hybridization market is segmented into product, technology, application, end user, and region. FISH uses fluorescently labeled DNA probes to detect or confirm the presence of genes or chromosomal abnormalities. It is also used in clinical research for the prenatal diagnosis of inherited chromosomal aberrations and postnatal diagnosis of carriers of genetic diseases. FISH is considered more reliable, sensitive, and accurate as compared to IHC; moreover, this test does not require expensive equipment.

In 2021, the hospitals and diagnostic laboratories ranked first in terms of revenue in the in situ hybridization market.

Based on end users, the global in situ hybridization market is segmented into hospitals and diagnostic laboratories, academic & research institutes, contract research organizations (CROs), and pharmaceutical & biotechnology companies. In 2021, the hospitals and diagnostic laboratories segment accounted for the largest share of the in situ hybridization market, due to an increasing number of molecule-based screenings, the increasing number of specialty diagnostic tests performed in hospital laboratories, the rising number of in-house diagnostic procedures, and the rising trend of establishing in-house diagnostic capabilities in hospitals.

Driver: Rising incidence of genetic disorders and cancer

Clinical trials pertaining to genetic disorders increased most significantly in the Asia Pacific region. The number of trials conducted increased by 184% between 2010 and 2020. Japan accounted for the largest share, with 28.4% of all trials in the region taking place in Japan in 2020. Australia (25%) and China (21.6%) accounted for the second- and third-largest shares of the overall number of ongoing trials in the region. Moreover, Southeast Asians are more likely to have genetic disorders, according to a study led by co-senior authors Dr. Kumaraswamy Thangaraj of the CSIR-Centre for Cellular and Molecular Biology (CCMB) and Dr. David Reich of the Broad Institute of MIT and Harvard, Cambridge, US, in collaboration with other institutes.

Challenge: Shortage of skilled professionals

In Situ hybridization requires high technical know-how. For instance, understanding of the molecular information of a chromosome or a gene is crucial for conducting ISH tests. Moreover, there is a reluctcance to move from tradional approaches to IT-based approaches such as in situ hybridization. Thus, the shortage of skilled professionals for conducting in situ hybridization tests will hinder the market growth over the forecast period.

Japan was the largest market for Asia Pacific in situ hybridization in 2021.

Companies in Japan are increasingly focusing on revolutionizing the field of precision oncology and personalized medicine with the integration of genetics and proteomics diagnosis. Several collaborations have been observed in the country, which support the research industry in Japan. This trend is expected to continue in the coming years and contribute to market growth in Japan.

To curb the growing incidence of chronic diseases, the Japanese government has been taking initiatives for targeted treatments & personalized therapies, such as the establishment of the Center for Cancer Genomics and Advanced Therapeutics. This initiative is the focal point through which the government aims to aggregate and manage public information on genomic medicine. Efforts like these will also favor market growth in the country.

Inquiry Before Buying @

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=212028829

Recent Developments

• In 2022, RNAscope ISH Detection Kit manufactured by Bio-Techne received CE-IVD approval for the BOND-III platform (Leica Biosystems).
• In 2021, Applied Spectral Imaging (ASI) and KromaTiD, Inc. entered a strategic commercial partnership granting ASI worldwide rights to market KromaTiD’s proprietary Pinpoint FISH (PPF) probes and assay services.
• In 2020, Creative Bioarray introduced an advanced FISH probe to detect the 2019 Novel Coronavirus.

Key Market Players:

The market for in situ hybridization is competitive and highly consolidated, with key players strategizing to capture the market. Prominent players in the ISH market are Abbott Laboratories (US), Abcam (UK), Abnova Corporation (Taiwan), Agilent Technologies (US), Bio SB (US), Biocare Medical (US), BioGenex Laboratories (US), Bio-Rad Laboratories (US), Bio-Techne Corporation (US), BioView (Israel), Danaher (US), Enzo Biochem (US), F. Hoffmann-La Roche (Switzerland), Merck (Germany), NeoGenomics Laboratories (US), OpGen (US), PerkinElmer (US), QIAGEN (Germany), Thermo Fisher Scientific (US), and ZytoVision (Germany).

The Asia Pacific region is the fastest-growing region of the in situ hybridization market in 2021.

The Asia Pacific region is estimated to grow at the highest CAGR in the in situ hybridization market during the forecast period. China and India are the key revenue contributors to the Asia Pacific in situ hybridization market. Favorable government support for product approvals and the presence of major players in these countries are anticipated to drive regional market growth.

View detailed Table of Content here@

https://www.marketsandmarkets.com/Market-Reports/in-situ-hybridization-market-212028829.html

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are moulded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit MarketsandMarkets™ or follow us on Twitter, LinkedIn and Facebook.